WO1995011235A1 - Pyrimidinones as antiarthritic and anti-inflammatories - Google Patents

Pyrimidinones as antiarthritic and anti-inflammatories Download PDF

Info

Publication number
WO1995011235A1
WO1995011235A1 PCT/US1994/010571 US9410571W WO9511235A1 WO 1995011235 A1 WO1995011235 A1 WO 1995011235A1 US 9410571 W US9410571 W US 9410571W WO 9511235 A1 WO9511235 A1 WO 9511235A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
methyl
oxo
alkyl
dihydro
Prior art date
Application number
PCT/US1994/010571
Other languages
French (fr)
Inventor
Richard Allen Nugent
Stephen T. Schlachter
Original Assignee
The Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Upjohn Company filed Critical The Upjohn Company
Priority to JP7511063A priority Critical patent/JPH09504010A/en
Priority to AU77989/94A priority patent/AU7798994A/en
Priority to EP94928624A priority patent/EP0724573A1/en
Publication of WO1995011235A1 publication Critical patent/WO1995011235A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3

Definitions

  • the present invention is directed toward pyrimidinones and their pharmaceutically acceptable salts which are characterized by (Formula I) which are useful as anti-inflammatories and antiarthritic agents.
  • the present compounds are useful in humans and lower animals as a safe and effective treatment of chronic inflammatory diseases. These diseases include periodontal disease, rheumatoid arthritis, osteoarthritis, neuritis, bursitis, pneumoconioses, Crohn's disease, chronic inflammatory bowel disease, chronic asthma, atherosclerosis, multiple sclerosis, and sarcoidosis.
  • US Patent 4,746,654 discloses bisphosphonates useful as anti-inflammatory agents
  • Australian Patent A-51534/85 discloses bisphosphonates useful in treating abnormal calcium and phosphorous metabolism and useful in treating arthritis
  • US Patent 3,683,080 discloses polyphosphonates; in particular, diphosphonates useful in inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
  • European Patent Application 0 168 262 discloses an intermediate pyrimidine compound, Formula Vila which is similar to the subject compound except that the corresponding R 2 is only hydrogen or a lower alkyl. The compounds are described to be useful for treating hypertension and cerebrovascular disease.
  • the present invention is pyrimidinones or its pharmaceutically acceptable salts which are structurally represented by Formula I
  • R 2 is a) (CH 2 ) n -Y and i) where n is 1 then Y is C r C 6 alkoxy, morpholinyl, piperdinyl, pyrrolidinyl, phenoxy, phenylthio, phenylsulfonyl, phenylsulfinyl, -NHC(O)-C 1 -C 6 carboxylic acid, N 3 , NH 2 , diethylamino, hydrogen (provided R 4 is benzyloxy), halogen (provided R 3 is a C j -Cg alkyl) or CH("EWG") 2 where "EWG" is an electron withdrawing group each individually selected from the group consisting of CO 2 R or
  • R 3 is hydrogen or C j -C 8 alkyl
  • R 4 is hydrogen, hydroxyl, C j -C 8 alkyl, alkoxy, benzyloxy or phenoxy
  • R 5 is hydrogen, halogen, C j -C 8 alkyl, C j -C 8 alkoxy, phenoxy, C j -C 8 alkylthio, thiophenyl, NH 2 , Aryl (except that R 5 is other than phenyl when R 4 and Y are both hydrogen) or Heteroaryl;
  • R 6 is H, C j -C 8 alkyl, benzyl, phenyl, phenyl substituted with one to five F, Cl, Br, I, NO 2 , OCH 3 or C r C 4 alkyl;
  • R 7 is H, C j -C alkyl, benzyl, phenyl, phenyl substituted with one to five F, Cl, Br, I, NO 2 , OCH g or C j -C ⁇ alkyl, or where both R 7 's are taken together to form a CH 2 - CH , CH 2 -CH 2 -CH 2 or CH 2 -C(CH 3 ) 2 -CH 2 whereby a heterocyclic ring containing the bonded P atom and the two O atoms is formed.
  • the present invention comprises the use of these compounds in humans and lower animals as a safe and effective treatment of chronic inflammatory diseases.
  • the invention is a method for treating inflammation by administering to a patient (animals, including humans) in need of such treatment an anti-inflammatory effective amount of a compound of Formula I.
  • routes of administration include oral, intramuscular, intravenous, transdermal, intra-articular, subcutaneous, or intraperitoneal.
  • An effective amount is an amount whereby the symptoms of inflammation or arthritis such as pain and discomfort are relieved or reduced or mobility of the affected area is increased.
  • a typical dosage is about 0.001 mg to 1.0 gram with dose determined by the particular mode of administration, use and frequency of administration.
  • the present invention comprises pyrimidinones and their pharmaceutically acceptable salts which are characterized by (Formula I, above) and which are useful as anti-inflammatories and anti-arthritic agents. These compounds are particularly useful in the treatment of arthritis and its associated symptoms such as inflammation and excessive bone growth or remodelling.
  • Formula I the variable designations are further defined as follows.
  • C-C j defines the number of carbon atoms present from the integer "i" to the integer "j” inclusive.
  • C j -C 8 alkyl refers to alkyl of 1-3 carbon atoms, inclusive, or methyl, ethyl, propyl, and isopropyl.
  • C j -C 8 alkyl is methyl, ethyl, propyl, butyl, pentyl, hexyl, and isomeric forms thereof.
  • aAryl means phenyl or naphthyl.
  • Heteroaryl means morpholinyl, piperazinyl, piperidinyl, imidazolidinyl, pyrazolidinyl, isoxazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl or pyridazinyl.
  • halogen includes fluoro, chloro, bromo and iodo.
  • Pharmaceutically acceptable salts means salts useful for administering the compounds of this invention or useful forms the compounds may take in vitro or in vivo and include potassium, sodium, hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, mesylate, maleate, malonate, succinate, tartrate, citric acid and the like. These salts may be in hydrated form.
  • pyrimidinones and derivatives (Formula I) useful as anti-inflammatories and antiarthritics are prepared as shown in Examples 1-35 and in Table 1, below.
  • the Formula I compounds of this invention have been tested in a Delayed Type Hypersensitivity Granuloma Assay (DTH GRA) model for inflammation.
  • DTH GRA Delayed Type Hypersensitivity Granuloma Assay
  • mice have a DTH granuloma (DTH GRA) lesion induced by subcutaneously implanting a mBSA-soaked filter which is excised after nine days.
  • DTH GRA DTH granuloma
  • Compounds are administered to the mice to determine their effect on the lesions. The results are recorded as percent inhibition. The larger the inhibition, the more effective the compound. Inhibition of 10 to 20% is considered to indicate anti- granuloma activity. Greater than 30% inhibition is good activity.
  • the DTH GRA data obtained from the compounds of Formula 1 are shown in the Table 2, below. The compounds are scored as having anti-inflammatory activity at 10-20% inhibition and good activity at greater than 30% inhibition.
  • Example 2 Made by the same method of Example 2 were Examples 3-6, whose compounds are identified below.
  • EXAMPLE 3 4(3H)-Pyrimidinone, 3-methyl-6-phenyl-2-[(phenylthio)methyl]-
  • EXAMPLE 4 Phosphonic acid, [2-(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl) ethylidene]bis-, tetraethyl ester
  • R 3 is methyl
  • R 4 is hydrogen
  • R 5 is phenyl
  • R 2 is -CH 2 -CH-(PO(OEt) 2 ) 2 , mp 86-88°C.
  • EXAMPLE 5 Propanedioic acid, [(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl)methyl]-, diethyl ester
  • R 3 is methyl
  • R 4 is hydrogen
  • R 5 is phenyl
  • R 2 is -CH 2 -CH-(CO 2 Et) 2 , mp 102-103°C.
  • EXAMPLE 6 2-Pyrimidinepropanoicacid,.alpha.-(diethoxyphosphinyl)-l,6- dihydro-1- methyl-6-oxo-4-phenyl-, ethyl ester
  • R 3 is methyl
  • R 4 is hydrogen
  • R 5 is phenyl
  • R 2 is -CH 2 -CH(CO 2 Et)(PO(OEt) 2 ), mp 119°C.
  • Example 7 Made by the same method of Example 7, the title compound was prepared, mp 133-134°C.
  • Example 7 Made by the same method of Example 7, the title compound was prepared, mp 84-85°C.
  • EXAMPLE 12 4(3H)-Pyrimidinone, 2-(aziodomethyl)-3-methyl-6-phenyl- 4(3H)-Pyrimidinone, 2-(iodomethyl)-3-methyl-6-phenyl- (4.06 g, 12.4 mmol) was treated with sodium azide (1.62 g, 24.9 mmol) and acetonitrile (25 ml) and stirred at 22°C for 60 hours then concentrated in vacuo. The residue was dissolved in methylene chloride, washed with saturated NaHCO 3 , 3x IM NaHSO 3 , saturated NaCl, dried with MgSO 4 , and concentrated in vacuo (40%), mp 111-112°C.
  • EXAMPLE 15 Butanoic acid, 4-[[(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl) methyl] amino]-4-oxo- 4(3H)-Pyrimidinone, 2-(aminomethyl)-3-methyl-6-phenyl- (304 mg, 1.41 mmol) dissolved in chloroform (5 ml) was treated with succinic anhydride (141 mg, 1.41 mmol) then heated to reflux for 1 hour. The resultant solid was filtered, washed with chloroform and dried: 0.377 g, (1.20 mmol, 85%), mp 200-201°C.
  • Example 15 In a similar to Example 15 manner the title compound was prepared: from glutaric anhydride (62%), mp 181-182°C.
  • Benzenesulfinic acid, sodium salt (0.346 g, 2.1 mmol) was slurried in toluene (5 ml), then treated with 4(3H)-Pyrimidinone, 2-(iodomethyl)-3-methyl-6-phenyl- (0.517 g, 1.6 mmol) and heated to 70°C for 20 hours. The reaction was cooled to room temperature and most of the solvent was removed in vacuo. The residue was dissolved in methylene chloride, washed thrice with saturated NaHCO g and IM NaHSO g , dried with MgSO 4 , and concentrated in vacuo.
  • title compound was prepared from glutaric anhydride (26%), mp 170-171°C.
  • EXAMPLE 22 Phosphonic acid, [(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl)cyclopropylidene]bis-,tetraethyl ester
  • EXAMPLE 25 Propanedioic acid, [2-(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyDethyl]-, bis(l,l-dimethylethyl) ester 4(3H)-Pyrimidmone, 2,3-dimethyl-6-phenyl (0.744 g, 3.72 mmol) was dissolved in THF (37 ml), cooled to -78°C, then treated with lithium bis(trimethylsilyl)amide (4.1 ml, 4.1 mmol).
  • the ester (22.10 g, 0.113 mol) was dissolved in THF (5 ml) and added slowly to a -78°C solution of LiHMDS (1 M in THF, 230 ml, 0.230 mol). After stirring for 45 minutes, benzoyl chloride (13.1 ml, 0.113 mol) was added and the reaction warmed to room temperature for 45 minutes. It was quenched with 1 N HC1, extracted thrice with methyl t-butyl ether, dried with MgSO 4 , and stripped: 45.68 g (0.153 mol).
  • the crude material, acetamidine hydrochloride (28.95 g, 0.306 mol), and 25% sodium methoxide/methanol (77 ml, 0.336 mol) were combined and heated to reflux for 36 hours. It was cooled, diluted with water, and pH adjusted to 7 with concentrated HC1. The precipitate was collected, washed with cold ether, and air dried: 20.45 g (70.00 mmol, 62%), mp 168°C.
  • the pyrimidinone (5.84 g, 20.0 mmol), K g CO g (3.20 g, 23 mmol), and methyl iodide (3.7 ml, 60 mmol) were heated in refluxing methanol (50 ml) overnight. The reaction was cooled and seeded. The precipitate was collected, washed with water and dried in the oven: 5.052 g (16.49 mmol, 82%), mp 118-119°C.
  • EXAMPLE 28 Phosphonic acid, [3-(l,6-dihydro-5-hydroxy-l-methyl-6-oxo-4- phenyl-2-pyrimidinyl)propylidene]bis-, tetraethyl ester Phosphonic acid, [3-[l,6-dihydro-l-methyl-6-oxo-4-phenyl-5-(phenylmethoxy)-2- pyrimidinyl]propylidene]bis-, tetraethyl ester (1.60 g, 2.64 mmol) in ethanol (50 ml) was treated with 10% Pd/C (320 mg) and ammonium formate (4.00 g), then heated to reflux for 2 hours.
  • the catalyst was removed by filtering through Celite and stripped. The residue was dissolved in methylene chloride, filtered through a short pad of silica gel and the pad was washed well with acetone. After concentration, the crude material was recrystallized from methyl t-butyl ether: 884 mg (1.71 mmol, 65%), mp 138-139°C.
  • Hydrogen chloride gas (2.0 g, 55 mmol) was slowly bubbled into acetonitrile (7.5 ml).
  • EXAMPLE 31 4(3H)-Pyrimidinone,2,3-dimethyl-6-phenylthio- Sodium hydride (0.36 g, 7.5 mmol) slurried in dimethyl formamide (25 ml) was treated with thiophenol (0.73 ml, 7.12 mmol) and 6-chloro-2,3-dimethyl-4(3H)- pyrimidinone (1.13 g, 7.13 mmol). The mixture was stirred at 22°C for 24 hours then diluted with H 2 O (70 ml).
  • EXAMPLE 32 4(3H)-Pyrimidinone, 2,3-dimethyl-6-piperidinyl 4(3H)-Pyrimidinone, 6-chloro-2,3-dimethyl- (0.778 g, 4.90 mmol) was slurried in piperidine (15 ml) and the solution was heated to reflux for 1 hour, then at 60°C for 18 hours. The reaction mixture was filtered through Celite and concentrated in vacuo. The residue was dissolved in methylene chloride and washed with 6% NaHCO 3 , 2 x H 2 O, then dried with MgSO 4 .

Abstract

Compounds useful in the treatment of inflammation structurally represented as formula (I) or pharmaceutically acceptable salts thereof, wherein R2 is a) (CH¿2?)n-Y i) where n is 1 then Y is C1-C6 alkoxy, morpholinyl, piperdinyl, pyrrolidinyl, phenoxy, phenylthio, phenylsulfonyl, phenylsulfinyl, -NHC(O)-C1-C6 carboxylic acid, N3, NH2, diethylamino, hydrogen (provided R?4¿ is benzyloxy), halogen (provided R3 is a C¿1?-C6 alkyl) or CH('EWG')2 where 'EWG' is an electron withdrawing group each individually selected from the group consisting of CO2R?6¿ or PO(OR7)2, or ii) n is 2 then Y is CH('EWG')2, or b) a terminal olefin substituted with i) an aryl or heteroaryl, ii) hydroxyl and a C1-C6 alkyl, phenyl or (CH2)m-CO2R6 where m is 1 to 3, or c) C¿3?-C6 cycloalkyl (optionally substituted with a halogen, (PO(OC2H5)2)2 or CN); R?3¿ is hydrogen or C¿1?-C6 alkyl; R?4¿ is hydrogen, hydroxyl, C¿1?-C6 alkyl, alkoxy, benzyloxy or phenoxy; R?5¿ is hydrogen, halogen, C¿1?-C6 alkyl, C1-C6 alkoxy, phenoxy, C1-C6 alkylthio, thiophenyl, NH2, aryl (except that R?5¿ is other than phenyl when R4 and Y are both hydrogen) or heteroaryl; R6 is H, C¿1?-C6 alkyl, benzyl, phenyl, phenyl substituted with one to five F, C1, Br, I, NO2, OCH3 or C1-C4 alkyl; and R?7¿ is H, C¿1?-C6 alkyl, benzyl, phenyl, phenyl substituted with one to five F, C1, Br, I, NO2, OCH3 or C1-C4 alkyl, or where both R?7¿'s are taken together to form a CH¿2?-CH2, CH2-CH2-CH2 or CH2-C(CH3)2-CH2 whereby a heterocyclic ring containing the bonded P atom and the two O atoms is formed. The compounds are useful as anti-inflammatory and antiarthritic agents.

Description

PYRIMIDINONES AS ANTIARTHRITIC AND ANTI-INFLAMMATORIES
BACKGROUND OF THE INVENTION The present invention is directed toward pyrimidinones and their pharmaceutically acceptable salts which are characterized by (Formula I) which are useful as anti-inflammatories and antiarthritic agents.
The present compounds are useful in humans and lower animals as a safe and effective treatment of chronic inflammatory diseases. These diseases include periodontal disease, rheumatoid arthritis, osteoarthritis, neuritis, bursitis, pneumoconioses, Crohn's disease, chronic inflammatory bowel disease, chronic asthma, atherosclerosis, multiple sclerosis, and sarcoidosis.
DESCRIPTION OF THE RELATED ART For state of the art purposes, US Patent 4,746,654 discloses bisphosphonates useful as anti-inflammatory agents; Australian Patent A-51534/85 discloses bisphosphonates useful in treating abnormal calcium and phosphorous metabolism and useful in treating arthritis; and US Patent 3,683,080 discloses polyphosphonates; in particular, diphosphonates useful in inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
European Patent Application 0 168 262 discloses an intermediate pyrimidine compound, Formula Vila which is similar to the subject compound except that the corresponding R2 is only hydrogen or a lower alkyl. The compounds are described to be useful for treating hypertension and cerebrovascular disease.
SUMMARY OF THE INVENTION
In one aspect, the present invention is pyrimidinones or its pharmaceutically acceptable salts which are structurally represented by Formula I
Figure imgf000003_0001
wherein R2 is a) (CH2)n-Y and i) where n is 1 then Y is CrC6 alkoxy, morpholinyl, piperdinyl, pyrrolidinyl, phenoxy, phenylthio, phenylsulfonyl, phenylsulfinyl, -NHC(O)-C1-C6 carboxylic acid, N3, NH2, diethylamino, hydrogen (provided R4 is benzyloxy), halogen (provided R3 is a Cj-Cg alkyl) or CH("EWG")2 where "EWG" is an electron withdrawing group each individually selected from the group consisting of CO2R or
PO(OR7)2, or ii) where n is 2 then Y is CH("EWG")2, or b) a terminal olefin substituted with i) an Aryl or Heteroaryl, ii) hydroxyl and a Cj-C8 alkyl, phenyl or (CH2)m-CO2R6 where m is 1 to 3, or c) C8-C8 cycloalkyi (optionally substituted with a halogen, (PO(OC2H5)2)2 or CN;
R3 is hydrogen or Cj-C8 alkyl; R4 is hydrogen, hydroxyl, Cj-C8 alkyl, alkoxy, benzyloxy or phenoxy;
R5 is hydrogen, halogen, Cj-C8 alkyl, Cj-C8 alkoxy, phenoxy, Cj-C8 alkylthio, thiophenyl, NH2, Aryl (except that R5 is other than phenyl when R4 and Y are both hydrogen) or Heteroaryl;
R6 is H, Cj-C8 alkyl, benzyl, phenyl, phenyl substituted with one to five F, Cl, Br, I, NO2, OCH3 or CrC4 alkyl; and
R7 is H, Cj-C alkyl, benzyl, phenyl, phenyl substituted with one to five F, Cl, Br, I, NO2, OCHg or Cj-C^ alkyl, or where both R7's are taken together to form a CH2- CH , CH2-CH2-CH2 or CH2-C(CH3)2-CH2 whereby a heterocyclic ring containing the bonded P atom and the two O atoms is formed. In another aspect, the present invention comprises the use of these compounds in humans and lower animals as a safe and effective treatment of chronic inflammatory diseases. These diseases include periodontal disease, rheumatoid arthritis, osteoarthritis, pneumoconioses, Crohn's disease, chronic inflammatory bowel disease, chronic asthma, atherosclerosis, multiple sclerosis, and sarcoidosis. In yet another aspect, the invention is a method for treating inflammation by administering to a patient (animals, including humans) in need of such treatment an anti-inflammatory effective amount of a compound of Formula I. Routes of administration include oral, intramuscular, intravenous, transdermal, intra-articular, subcutaneous, or intraperitoneal. An effective amount is an amount whereby the symptoms of inflammation or arthritis such as pain and discomfort are relieved or reduced or mobility of the affected area is increased. A typical dosage is about 0.001 mg to 1.0 gram with dose determined by the particular mode of administration, use and frequency of administration.
DETAILED DESCRIPTION OF THE INVENTION The present invention comprises pyrimidinones and their pharmaceutically acceptable salts which are characterized by (Formula I, above) and which are useful as anti-inflammatories and anti-arthritic agents. These compounds are particularly useful in the treatment of arthritis and its associated symptoms such as inflammation and excessive bone growth or remodelling. In Formula I, the variable designations are further defined as follows.
The carbon content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C-Cj defines the number of carbon atoms present from the integer "i" to the integer "j" inclusive. Thus, Cj-C8 alkyl refers to alkyl of 1-3 carbon atoms, inclusive, or methyl, ethyl, propyl, and isopropyl.
With respect to the above, Cj-C8 alkyl is methyl, ethyl, propyl, butyl, pentyl, hexyl, and isomeric forms thereof. "aAryl" means phenyl or naphthyl. "Heteroaryl" means morpholinyl, piperazinyl, piperidinyl, imidazolidinyl, pyrazolidinyl, isoxazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl or pyridazinyl. The term "halogen" includes fluoro, chloro, bromo and iodo. "Terminal olefin" means -CH=CH2 which can then have one or both of the terminal hydrogens substituted as indicated.
Pharmaceutically acceptable salts means salts useful for administering the compounds of this invention or useful forms the compounds may take in vitro or in vivo and include potassium, sodium, hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, mesylate, maleate, malonate, succinate, tartrate, citric acid and the like. These salts may be in hydrated form.
The pyrimidinones and derivatives (Formula I) useful as anti-inflammatories and antiarthritics are prepared as shown in Examples 1-35 and in Table 1, below.
The Formula I compounds of this invention have been tested in a Delayed Type Hypersensitivity Granuloma Assay (DTH GRA) model for inflammation. This assay is described by Dunn, C. J. et al., "Development of a delayed-type hypersensitivity granuloma model in the mouse for the study of chronic immune-mediated inflammatory disease," Agents and Actions, 27, 3/4 (1989) and "Murine Delayed-Type Hypersensitivity Granuloma," Int. J. Immunopharmc., 12, 8:899-904 (1990). Briefly, mBSA-sensitized mice have a DTH granuloma (DTH GRA) lesion induced by subcutaneously implanting a mBSA-soaked filter which is excised after nine days. Compounds are administered to the mice to determine their effect on the lesions. The results are recorded as percent inhibition. The larger the inhibition, the more effective the compound. Inhibition of 10 to 20% is considered to indicate anti- granuloma activity. Greater than 30% inhibition is good activity. The DTH GRA data obtained from the compounds of Formula 1 are shown in the Table 2, below. The compounds are scored as having anti-inflammatory activity at 10-20% inhibition and good activity at greater than 30% inhibition.
The "compound designations" correspond to the Examples' designations. The particular compounds designated are as follows:
TABLE 1
Figure imgf000006_0001
Figure imgf000007_0001
ot compoun s o t e nventon
TABLE 2
Dose % Inhibition % Inhibition
Example (mpk) Wet Weight Dry Weight
1 10 47 54
2 10 28 37
3 10 21 30
4 10 31 35
5 10 51 53
7 10 64 68
12 10 39 48
15 10 64 60
16 10 52 52
17 10 20 24
18 10 26 26
19 10 46
20 10 20 28
21 10 35 43
22 10 10 28
23 10 22 24
24 10 27 24
25 10 51 40
26 10 71 60
28 10 57 46
EXAMPLE 1: 4(3H)-Pyrimidinone, 2-(chloromethyl)-3-methyl-6-phenyl-
Procedure A:
4(3H)-Pyrimidinone, 2,3-dimethyl-6-phenyl (11.0 g, 54.9 mmol) in THF (55 ml) was added slowly to a -78°C solution of LiHMDS (IM in THF, 60 ml, 60 mmol). After stirring for 45 minutes, this was then cannulated into a -40°C solution of hexachloroethane (13.64 g, 57.6 mmol) in THF (50 ml) over a period of 45 minutes. The reaction was warmed to room temperature for 1 hour, then quenched with NH4C1, extracted thrice with ethyl acetate, washed with saturated NaHCO3 and brine, dried with MgSO4, and concentrated in vacua. The product was recrystallized from methyl t-butyl ether: 6.555 g (27.9 mmol, 51%), mp 121-122°C.
EXAMPLE 2: 4(3H)-Pyrimidinone, 3-methyl-2-(phenoxymethyl)-6-phenyl-
Procedure B: To a 0°C suspension of sodium hydride (0.191 g, 3.98 mmol) in toluene (9 ml) was added phenol (0.34 g, 3.61 mmol). After 15 minutes,
2-(chloromethyl)-3-methyl-6-phenyl-4(3H)- pyrimidinone (0.775 g, 3.2 mmol) was added and the reaction heated to reflux for 2.5 hours. After cooling, the reaction mixture was diluted with methylene chloride, then washed thrice with saturated NaHCO3, dried with MgSO4 and concentrated in vacuo (57%), mp 104-105°C.
Made by the same method of Example 2 were Examples 3-6, whose compounds are identified below.
EXAMPLE 3: 4(3H)-Pyrimidinone, 3-methyl-6-phenyl-2-[(phenylthio)methyl]- The compound of Formula I where R3 is methyl; R4 is hydrogen; R5 is phenyl; and R2 is -CH2-S-Phenyl, mp 94-95°C.
EXAMPLE 4: Phosphonic acid, [2-(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl) ethylidene]bis-, tetraethyl ester The compound of Formula I where R3 is methyl; R4 is hydrogen; R5 is phenyl; and R2 is -CH2-CH-(PO(OEt)2)2, mp 86-88°C.
EXAMPLE 5: Propanedioic acid, [(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl)methyl]-, diethyl ester The compound of Formula I where R3 is methyl; R4 is hydrogen; R5 is phenyl; and R2 is -CH2-CH-(CO2Et)2, mp 102-103°C.
EXAMPLE 6: 2-Pyrimidinepropanoicacid,.alpha.-(diethoxyphosphinyl)-l,6- dihydro-1- methyl-6-oxo-4-phenyl-, ethyl ester The compound of Formula I where R3 is methyl; R4 is hydrogen; R5 is phenyl; and R2 is -CH2-CH(CO2Et)(PO(OEt)2), mp 119°C.
EXAMPLE 7: 4(3H)-Pyrimidinone, 3-methyl-2-(4-morpholinylmethyl)- 6-phenyl- Procedure C:
2-(chloromethyl)-3-methyl-6-phenyl-4(3H)-pyrimidinone (0.507 g, 2.2 mmol) in THF (12 ml) was treated with morpholine (0.40 ml, 4.5 mmol), then heated to reflux for 1.5 hours. The reaction mixture was cooled, filtered through a pad of Celite, and concentrated in vacuo. The residue was dissolved in methylene chloride and filtered a second time. The organic layer was concentrated in vacuo to provide a light yellow solid. Crude material was purified by recrystallization from ethyl acetate (27%), mp 135-136°C.
EXAMPLE 8: 4(3H) -Pyrimidinone, 3-methyl-6-phenyl-2-piperidinyl-
Made by the same method of Example 7, the title compound was prepared, mp 133-134°C.
EXAMPLE 9: 4(3H)-Pyrimidinone, 3-methyl-6-phenyl-2-pyrrolidinyl-
Made by the same method of Example 7, the title compound was prepared, mp 112-113°C.
EXAMPLE 10: 4(3H) -Pyrimidinone, 2-dimethylamino-3-methyl-6-phenyl-
Made by the same method of Example 7, the title compound was prepared, mp 84-85°C.
EXAMPLE 11: 4(3H)-Pyrimidinone, 2-methoxy-3-methyl-6-phenyl-
Made by the same method of Example 7, the title compound was prepared, mp 86-87°C.
EXAMPLE 12: 4(3H)-Pyrimidinone, 2-(aziodomethyl)-3-methyl-6-phenyl- 4(3H)-Pyrimidinone, 2-(iodomethyl)-3-methyl-6-phenyl- (4.06 g, 12.4 mmol) was treated with sodium azide (1.62 g, 24.9 mmol) and acetonitrile (25 ml) and stirred at 22°C for 60 hours then concentrated in vacuo. The residue was dissolved in methylene chloride, washed with saturated NaHCO3, 3x IM NaHSO3, saturated NaCl, dried with MgSO4 , and concentrated in vacuo (40%), mp 111-112°C.
EXAMPLE 13: 4(3H)-Pyrimidinone, 2-(iodomethyl)-3-methyl-6-phenyl-
2-(chloromethyl)-3-methyl-6-phenyl-4(3H)-pyrimidinone (0.98 g, 4.16 mmol) and sodium iodide (0.654 g, 4.37 mmol) were combined in acetone (10 ml) and heated to reflux for 30 minutes. The reaction mixture was cooled, filtered and concentrated in vacuo. The resulting solid was dried under high vacuum to recover a bright yellow solid. EXAMPLE 14: 4(3H)-Pyrimidinone, 2-(aminomethyl)-3-methyl-6-phenyl-
2-(chloromethyl)-3-methyl-6-phenyl-4(3H)-pyrimidinone (3.98 g, 17.0 mmol) and sodium azide (2.21 g, 34 mmol) were combined in acetonitrile (25 ml) and heated to a gentle reflux for 1 hour. After cooling to room temperature, the solvent was removed in vacuo. The residues were diluted with methylene chloride and washed with 6% NaHCOg, H2O, and brine, treated with charcoal and filtered through a pad of MgSO4. After concentration in vacuo, the crude product was resuspended in a mixture of ethanol (80 ml) with 5% palladium on carbon (0.4 g) and hydrogenated in an atmosphere of hydrogen for 2 hours. The reaction mixture was filtered through Celite and concentrated in vacuo. The product was recrystallized from ethyl acetate/hexane: 0.80 g (3.7 mmol, 22%), mp 90-92°C.
EXAMPLE 15: Butanoic acid, 4-[[(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl) methyl] amino]-4-oxo- 4(3H)-Pyrimidinone, 2-(aminomethyl)-3-methyl-6-phenyl- (304 mg, 1.41 mmol) dissolved in chloroform (5 ml) was treated with succinic anhydride (141 mg, 1.41 mmol) then heated to reflux for 1 hour. The resultant solid was filtered, washed with chloroform and dried: 0.377 g, (1.20 mmol, 85%), mp 200-201°C.
EXAMPLE 16: Pentanoic acid, 5-[[(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl) methyl] amino]-5-oxo-
In a similar to Example 15 manner the title compound was prepared: from glutaric anhydride (62%), mp 181-182°C.
EXAMPLE 17: 4(3H)-Pyrimidinone, 3-methyl-6-phenyl-2-[(phenylsulfonyl)- methyl]-
Benzenesulfinic acid, sodium salt (0.346 g, 2.1 mmol) was slurried in toluene (5 ml), then treated with 4(3H)-Pyrimidinone, 2-(iodomethyl)-3-methyl-6-phenyl- (0.517 g, 1.6 mmol) and heated to 70°C for 20 hours. The reaction was cooled to room temperature and most of the solvent was removed in vacuo. The residue was dissolved in methylene chloride, washed thrice with saturated NaHCOg and IM NaHSOg, dried with MgSO4, and concentrated in vacuo. The product was purified by chromatography on silica gel: 226 mg'(0.66 mmol, 41%), mp 174-175°C. EXAMPLE 18: 4(3H)-Pyrimidinone, 3-methyl-6-phenyl-2-[(phenylsulfinyl)- methyl]-
4(3H)-Pyrimidinone, 3-methyl-6-phenyl-2-[(phenylthio)methyl]- (0.589 g, 1.91 mmol) dissolved in methanol (10 ml) at 0°C was treated with an aqueous solution of oxone (7.23 g, 5.7 mmol) in water (21 ml). The reaction mixture was stirred at 0°C for 5 hours, then treated with IM NaHSO3 and concentrated in vacuo while heating the sample to 40°C. Methylene chloride was added and after separation, the organic layer was washed 3x IM NaHSO3, saturated NaHCOg, dried with MgSO4 and concentrated in vacuo. The sample was purified by chromatography on silica gel: 217 mg (0.67 mmol, 35%), mp 158-159°C.
EXAMPLE 19: 4-Pentenoic acid, 5-(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl)-4-hydroxy-, (Z)-
4(3H)-Pyrimidinone, 2,3-dimethyl-6-phenyl (5.45 g, 27.2 mmol) was dissolved in THF (25 ml), cooled to -20°C, and treated with LiHMDS (IM in THF, 60 ml, 60 mmol).
After stirring for 30 minutes, succinic anhydride (3.0 g, 30.0 mmol) was added and the reaction warmed to room temperature for 2 hours. It was quenched with water, extracted twice with ethyl acetate, and the aqueous solution was acidified with IN HC1 then filtered. The product was recrystallized from iPrOH: 4.30 g (14.3 mmol, 53%), mp 232-233°C.
EXAMPLE 20: 5-Hexenoic acid, 6-(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl)-5-hydroxy-, (Z)-
In a similar manner to Example 19, title compound was prepared from glutaric anhydride (26%), mp 170-171°C.
EXAMPLE 21: 4-Pentenoic acid, 5-(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl)-4-hydroxy-, methyl ester, (Z)-
4-Pentanoic acid, 5-( l,6-dihydro-l-methyl-6-oxo-4-phenyl-2-pyrimidinyl)- 4-hydroxy-, (Z)-(693 mg, 2.31 mmol) in methanol (25 ml) and H2SO4 (1 drp) was heated to reflux for 3 hours. After removing the bulk of the methanol in vacuo, the crystals were filtered and washed with ether: 646 mg (2.06 mmol, 89%), mp 153°C.
EXAMPLE 22: Phosphonic acid, [(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl)cyclopropylidene]bis-,tetraethyl ester
4(3H)-Pyrimidinone, 2-(chloromethyl)-3-methyl-6-phenyl- (705 mg, 3.0 mmol), ethenylidenebis(phosphonic acid), tetraethyl ester (900 mg, 3.0 mmol) and DBU (0.5 ml, 3.3 mmol) were stirred in THF(5 ml) at room temperature for 24 hours. The reaction was quenched with NH4C1, extracted thrice with ethyl acetate, dried with MgSO4, and stripped. The crude was purified by silica gel chromatography: 471 mg (0.95 mmol, 32%), NMR: δ (CDC13) 7.97 (m, 2H), 7.44 (m, 3H), 6.84 (s, IH), 4.39 (m, 4H), 4.1-3.8 (m, 4H), 3.75 (s, 3H), 2.99 (m, IH), 2.56 (m, IH), 1.95 (m, IH), 1.402 (t, J=7.2, 3H), 1.39 (t, J=7.2, 3H), 1.19 (t, J=7.2, 3H), 1.08 (t, J=7.2, 3H).
EXAMPLE 23: Cyclopropanecarbonitrile, 2-(l,6-dihydro-l-methyl-6-oxo-4- phenyl-2-pvrimidinyl)-, trans- By the same method in Example 22, the title compound was prepared, mp 166-
167°C.
EXAMPLE 24: Cyclopropanecarbonitrile, 2-(l,6-dihydro-l-methyl-6-oxo-4- phenyl-2-pyrimidinyl)-, cis- By the same method in Example 22, the title compound was prepared, mp 195-
196°C.
EXAMPLE 25: Propanedioic acid, [2-(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyDethyl]-, bis(l,l-dimethylethyl) ester 4(3H)-Pyrimidmone, 2,3-dimethyl-6-phenyl (0.744 g, 3.72 mmol) was dissolved in THF (37 ml), cooled to -78°C, then treated with lithium bis(trimethylsilyl)amide (4.1 ml, 4.1 mmol). .After stirring for 30 minutes at -78°C, a solution of 2-t-butylcarboxy-2- propenoic acid t-butyl ester (0.424 g, 1.86 mmol) in THF (10 ml) was added slowly over approximately 1 hour using a syringe pump. The reaction was quenched immediately with 4.1M NH4C1 (1 ml, 4.1 mmol) then warmed to 22°C. The reaction mixture was concentrated in vacuo and dissolved in ethyl acetate. The organic layer was washed 3x IN HC1, H2O, 3x NaHCOg and brine, then dried with MgSO4 and concentrated in vacuo. The crude mixture was chromatographed on silica gel: 0.317 g (0.74 mmol, 40%), mp 94-95°C.
EXAMPLE 26: 4(3H)-Pyrimidinone,2,3-dimethyl-6-phenyl-5-(phenylmethoxy)-
Sodium hydride (50% in oil, 19.2 g, 0.40 mol) was suspended in toluene (200 ml), then benzyl alcohol (43.2 g, 0.40 mol) was added dropwise. After stirring for 45 minutes, the gray foam was treated slowly with a solution of chloroacetic acid (18.8 g, 0.20 mol) in toluene (100 ml), then heated to reflux. After refluxing for 2 hours, the reaction was cooled to room temperature and poured onto water (100 ml). The organics were separated and the toluene extracted twice with water. The aqueous layer was washed with methyl t-butyl ether and the organics discarded. After adjusting the pH to 2 with concentrated HC1, the aqueous fraction was extracted thrice with methylene chloride, dried with MgSO4, and concentrated in vacuo: 29.50 g. This crude material, ethanol (40 ml), toluene (50 ml), and concentrated H2SO4 (3 ml) were heated to reflux overnight. .After cooling, it was washed with water, NaHCOg, dried with MgSO4, and concentrated in vacuo. The product was isolated by distillation: 24.38 g (0.126 mol, 63%) Bp0 1 55-60°C. This synthesis is essentially identical to that described in Aust. J. Chem. 1976, 29, 1335-1339. The ester (22.10 g, 0.113 mol) was dissolved in THF (5 ml) and added slowly to a -78°C solution of LiHMDS (1 M in THF, 230 ml, 0.230 mol). After stirring for 45 minutes, benzoyl chloride (13.1 ml, 0.113 mol) was added and the reaction warmed to room temperature for 45 minutes. It was quenched with 1 N HC1, extracted thrice with methyl t-butyl ether, dried with MgSO4, and stripped: 45.68 g (0.153 mol). The crude material, acetamidine hydrochloride (28.95 g, 0.306 mol), and 25% sodium methoxide/methanol (77 ml, 0.336 mol) were combined and heated to reflux for 36 hours. It was cooled, diluted with water, and pH adjusted to 7 with concentrated HC1. The precipitate was collected, washed with cold ether, and air dried: 20.45 g (70.00 mmol, 62%), mp 168°C. The pyrimidinone (5.84 g, 20.0 mmol), KgCOg (3.20 g, 23 mmol), and methyl iodide (3.7 ml, 60 mmol) were heated in refluxing methanol (50 ml) overnight. The reaction was cooled and seeded. The precipitate was collected, washed with water and dried in the oven: 5.052 g (16.49 mmol, 82%), mp 118-119°C.
EXAMPLE 27: Phosphonic acid, [3-[l,6-dihydro-l-methyl-6-oxo-4-phenyl-5-
(phenylmethoxy)-2-pyrimidinyl]propylidene]bis-, tetraethyl ester
To a -78°C solution of LiHMDS (1 M in THF, 8.4 ml, 8.4 mmol) was added a solution of 4(3H)-Pyrimidinone, 2,3-dimethyl-6-phenyl-5-(phenylmethoxy)- (1.23 g, 4.0 mmol) in THF/pyridine (1:1, 4 ml). After stirring for 30 minutes, ethenylidenebis(phosphonic acid), tetraethyl ester (2.52 g, 8.4 mmol) in THF (5 ml) was added and the reaction warmed to room temperature for 30 minutes. It was quenched with water, extracted thrice with ethyl acetate, washed once with IN HC1, NaHCO3, and brine, then dried with MgSO , and stripped. The sample was purified by silica gel chromatography: 1.937 g (3.19 mmol, 80%), NMR: δ (CDC13) 8.04 (m, 2H), 7.38 (m, 3H), 7.31 (m, 2H), 7.25 (m, 3H), 5.08 (s, 2H), 4.17 (m, 8H), 3.60 (s, 3H), 3.13 (t, J=7.2, 2H), 2.79 (tt, Jtl=6.6, Jt2=23.7, IH), 2.46 (m, 2H), 1.32 (m, 12H).
EXAMPLE 28: Phosphonic acid, [3-(l,6-dihydro-5-hydroxy-l-methyl-6-oxo-4- phenyl-2-pyrimidinyl)propylidene]bis-, tetraethyl ester Phosphonic acid, [3-[l,6-dihydro-l-methyl-6-oxo-4-phenyl-5-(phenylmethoxy)-2- pyrimidinyl]propylidene]bis-, tetraethyl ester (1.60 g, 2.64 mmol) in ethanol (50 ml) was treated with 10% Pd/C (320 mg) and ammonium formate (4.00 g), then heated to reflux for 2 hours. The catalyst was removed by filtering through Celite and stripped. The residue was dissolved in methylene chloride, filtered through a short pad of silica gel and the pad was washed well with acetone. After concentration, the crude material was recrystallized from methyl t-butyl ether: 884 mg (1.71 mmol, 65%), mp 138-139°C.
EXAMPLE 29: 4(3H)-Pyrimidinone, 6-chloro-2,3-dimethyl-
Hydrogen chloride gas (2.0 g, 55 mmol) was slowly bubbled into acetonitrile (7.5 ml). A second solution containing phosgene (4.9 g, 50 mmol) in acetonitrile (7.5 ml) was prepared in a pressure bottle and the HC1 solution was added to the pressure bottle.
The mixture was stoppered tightly and heated to 60-65°C for 64 hours. The solution was cooled to -78°C and filtered, then the solid was washed with a small amount of acetonitrile followed by washing with hexanes: 4.06 g (22.4 mmol, 45%). 6-chloro-2-methyl-4-pyrimidinone • HC1 (3.95 g, 21.7 mmol) and potassium carbonate (8.98 g, 65 mmol) were slurried in acetone (90 ml), iodomethane (3.4 ml, 54.2 mmol) was added and the solution refluxed for 2 hours. The reaction mixture was cooled and concentrated in vacuo. The residue was dissolved in methylene chloride and washed with saturated NH4C1, dried with MgSO4 and concentrated in vacuo: 3.3 g (20.8 mmol, 96%), mp 85-86°C.
EXAMPLE 30: 4(3H)-Pyrimidinone, 2,3-dimethyl-6-methoxy-
Diethyl malonate (28.6 g, 0.178 mol) was dissolved in methanol (180 ml) and acetamidine • HC1 added. The suspension was treated with 25% sodium methoxide in methanol (86 ml, 0.375 mol), heated to reflux for 3.5 hours, then cooled and diluted with sufficient H2O to dissolve the solids. The solution was cooled to 0°C and neutralized with concentrated HC1 to pH 6.5-6.0. The thick solid was filtered and dried on the filter to provide 14.1 g of crude material which was used directly in the next reaction. Compound is described in Collect. Czech. Chem. Commun., 32:1298-304 (1967).
The intermediate 6-hydroxy-2-methyl-4-pyrimidinone • HC1 (14.1 g, 0.11 mol) was slurried in methanol (160 ml) and treated with potassium carbonate (46.3 g, 0.33 mol) and iodomethane (28 ml, 0.45 mol), then heated to reflux for 45 hours. After cooling and concentration in vacuo, the residue was dissolved in H2O and washed 6 x with methylene chloride. The combined organics were concentrated in vacuo and the yellow oil solidified upon standing. Recrystallized from toluene /cyclohexane to recover an off-white solid which appeared to be slightly hygroscopic, 12.1 g, (67 mmol, 37%), mp 66-68°C.
EXAMPLE 31: 4(3H)-Pyrimidinone,2,3-dimethyl-6-phenylthio- Sodium hydride (0.36 g, 7.5 mmol) slurried in dimethyl formamide (25 ml) was treated with thiophenol (0.73 ml, 7.12 mmol) and 6-chloro-2,3-dimethyl-4(3H)- pyrimidinone (1.13 g, 7.13 mmol). The mixture was stirred at 22°C for 24 hours then diluted with H2O (70 ml). The aqueous solution was washed with ethyl acetate (50 ml) and after separation, hexane (50 ml) was added to the organic layer. The combined organics were washed 5 x H2O and brine, dried with MgSO4, then concentrated in vacuo. The pale yellow solid 4(3H)-Pyrimidinone,2,3-dimethyl- 6-phenylthio- was recrystallized from methyl t-butyl ether: 0.87 g (3.7 mmol, 53%), mp 105-106°C.
EXAMPLE 32: 4(3H)-Pyrimidinone, 2,3-dimethyl-6-piperidinyl 4(3H)-Pyrimidinone, 6-chloro-2,3-dimethyl- (0.778 g, 4.90 mmol) was slurried in piperidine (15 ml) and the solution was heated to reflux for 1 hour, then at 60°C for 18 hours. The reaction mixture was filtered through Celite and concentrated in vacuo. The residue was dissolved in methylene chloride and washed with 6% NaHCO3, 2 x H2O, then dried with MgSO4. The solvent was concentrated in vacuo and the orange oil was chromatographed on SiO2 with 10:1 ethyl acetate /methanol. The material 4(3H)-Pyrimidinone, 2,3-dimethyl-6-piperidinyl- recovered from the column was recrystallized from methyl t-butyl ether to provide 0.64 g, (3.1 mmol, 63%) of light brown crystals, mp 97-98°C.
EXAMPLE 33: 3-(l,6-Dihydro-4-chloro-l-methyl-6-oxo-2-pyrimidinyl)-propyli dene bisphosphonic acid, tetraethyl ester
4(3H)-Pyrimidinone, 6-chloro-2,3-dimethyl- (3.25 g, 20.5 mmol) dissolved in THF
(40 ml) was cooled to -78°C and treated with LiHMDS (21.5 ml, 21.5 mmol) and stirred for 1 hour. A solution of ethenylidenebis(phosphonic acid), tetraethyl ester (5.84 g, 19.5 mmol) in THF (10 ml) was added slowly and after 30 minutes at -78°C, the reaction mixture was warmed to 0°C for one hour. The reaction was quenched with saturated NH4C1 and concentrated in vacuo. The residue was dissolved in ethyl acetate and washed 3 x with saturated NH4C1, 3 x saturated NaHCOg and brine, dried with MgSO4, and concentrated in vacuo. The crude material 3-(l,6-Dihydro-4-chloro-l-methyl-6- oxo-2-pyrimidinyl)-propylidene bisphosphonic acid, tetraethyl ester was purified by chromatography on silica gel: 7.1 g (15.5 mmol, 79%) NMR: δ (CDC13) 6.35 (s, IH), 4.20- 4.04 (m, 8H), 3.47 (s, 3H), 3.08 (t, J=7.3, 2H), 2.62 (tt, Jtl=6.6, Jt2=23.8, IH), 2.43-2.25 (m, 2H), 1.29 (t, J=7.0, 12H).
EXAMPLE 34: 3-(l,6-Dihydro-l-methyl-6-oxo-4-phenylthio-2-pyrimidinyl)-pr opylidene bisphosphonic acid, tetraethyl ester
In a similar manner the title compound was prepared from 4(3H)-Pyrimidinone,
2,3-dimethyl-6-phenylthio-: (88%), NMR: δ (CDC13) 7.58-7.55 (m, 2H), 7.48-7.43 (m, 3H),
5.67 (s, IH), 4.28-4.16 (dq, 8H), 3.47 (s, 3H), 3.10 (t, J=7.3, 2H), 2.72 (tt, Jtl=6.4, Jt2=24,
IH), 2.47-2.33 (m, 2H), 1.37 (t, J=7.0, 12H).
EXAMPLE 35: 3-(l,6-Dihydro-l-methyl-6-oxo-4-piperidinyl-2-pyrimidinyl)- propylidene bisphosphonic acid, tetraethyl ester
3-( l,6-Dihydro-4-chloro- l-methyl-6-oxo-2-pyrimidinyl)-propylidene bisphosphonic acid, tetraethyl ester (from Ex. 33) (1.17 g, 2.56 mmol) was added to piperidine (8 ml) and the solution was heated gently to 50-60°C for 2 hours. The solution was cooled and filtered through Celite and concentrated in vacuo. The resultant oil was chromatographed on SiO2: 0.83 g (1.63 mmol, 64%), NMR: δ (CDC13) 5.40 (s, IH), 4.24-
4.14 (m, 8H), 3.53-3.50 (m, 4H), 3.44 (s, 3H), 3.00 (t, J=7.3, 2H), 2.72 (tt, Jtl=6.7,
Jt2=24, IH), 2.49-2.34 (m, 2H), 1.68-1.57 (m, 6H), 1.34 (m, 12H).

Claims

WHAT IS CLAIMED
1. A compound of Formula I or pharmaceutically acceptable salts thereof wherein Formula I is
Figure imgf000018_0001
wherein R2 is a) (CH2)n-Y i) where n is 1 then Y is Cj-C8 alkoxy, morpholinyl, piperdinyl, pyrrolidinyl, phenoxy, phenylthio, phenylsulfonyl, phenylsulfinyl, -NHC(O)-C1-C8 carboxylic acid, N3, NH2, diethylamino, hydrogen (provided R4 is benzyloxy), halogen (provided R3 is a Cj-C8 alkyl) or CH("EWG")2 where "EWG" is an electron withdrawing group each individually selected from the group consisting of CO2R6 or PO(OR7)2, or ii) where n is 2 then Y is CH("EWG")2, b) a terminal olefin substituted with i) an Aryl or Heteroaryl, ii) hydroxyl and an Cj-C8 alkyl, phenyl or (CH2)m-CO2R6 where m is 1 to 3, or c) C3-C6 cycloalkyi (optionally substituted with a halogen, (PO(OC2H5)2)2 or CN); R3 is hydrogen or Cj-C8 alkyl;
R4 is hydrogen, hydroxyl, Cj-C8 alkyl, alkoxy, benzyloxy or phenoxy; R5 is hydrogen, halogen, Cj-C8 alkyl, Cj-C8 alkoxy, phenoxy, Cj-C8 alkylthio, thiophenyl, NH2, .Aryl (except that R5 is other than phenyl when R4 and Y are both hydrogen) or Heteroaryl; R6 is H, Cj-C8 alkyl, benzyl, phenyl, phenyl substituted with one to five F, Cl,
Br, I, NO2, OCH3 or CrC4 alkyl; and
R7 is H, Cj-Cg alkyl, benzyl, phenyl, phenyl substituted with one to five F, Cl, Br, I, NO2, OCH3 or Cj-^ alkyl, or where both R7's are taken together to form a CH2- CH2, CH2-CH2-CH2 or CH2-C(CH3)2-CH2 whereby a heterocychc ring containing the bonded P atom and the two O atoms is formed.
2. The compound of Claim 1 wherein R2 is -CH2-CH(CO2-C1-C6 alkyl)2, -CH2- CH[PO(O-CrC6 alkyl)2]2 (C-C3H3)-(PO(OC2H5)2)2 or -CH2-morpholinyl.
3. The compound of Claim 2 wherein said Cj-C8 alkyl is ethyl.
4. The compound of Claim 1 wherein R2 is a terminal olefin substituted with a hydroxyl and (CH2)m-CO2R6.
5. The compound of Claim 1 wherein said R3 is methyl.
6. The compound of Claim 1 wherein said R4 is hydrogen, benzyloxy or hydroxyl.
7. The compound of Claim 1 wherein said R5 is Cl, methoxy, phenyl, thiophenyl or piperidinyl.
8. The compound of Claim 1 where R3 is methyl, R4 is hydrogen and R5 is phenyl.
9. The compound of Claim 8 which is a) 4(3H)-Pyrimidinone, 2-(chloromethyl)-3-methyl-6-phenyl-; b) 4(3H)-Pyrimidinone, 3-methyl-2-(phenoxymethyl)-6-phenyl-; c) 4(3H)-Pyrimidinone, 3-methyl-6-phenyl-2-[(phenylthio)methyl]-; d)Phosphonic acid, [2-( 1,6-dihydro- l-methyl-6-oxo-4-phenyl-2-pyrimidinyl)- ethylidene]bis-, tetraethyl ester; e) Propanedioic acid,[( 1,6-dihydro- l-methyl-6-oxo-4-phenyl-2-pyrimidinyl)- methyl]-, diethyl ester; f) 2-Pyrimidinepropanoic acid, .alpha.-(diethoxyphosphinyl)-l,6-dihydro-l-methyl- 6-oxo-4-phenyl-, ethyl ester; g) 4(3H)-Pyrimidinone, 3-methyl-2-(4-morphohnylmethyl)-6-phenyl-; h) 4(3H)-Pyrimidinone, 3-methyl-6-phenyl-2-piperidinyl-; i) 4(3H)-Pyrimidinone, 3-methyl-6-phenyl-2-pyrrolidinyl-; j) 4(3H)-Pyrimidinone, 2-dimethylamino-3-methyl-6-phenyl-; k) 4(3H)-Pyrimidinone, 2-methoxy-3-methyl-6-phenyl-;
1) 4(3H)-Pyrimidinone, 2-(aziodomethyl)-3-methyl-6-phenyl-; m) 4(3H)-Pyrimidinone, 2-(iodomethyl)-3-methyl-6-phenyl-; n) 4(3H)-Pyrimidinone, 2-(aminomethyl)-3-methyl-6-phenyl-; o) Butanoic acid, 4-[[(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2-pyrimidinyl) methyl]amino]-4-oxo- ; p) Pentanoic acid, 5-[[(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2-pyrimidinyl)methyl] amino]-5-oxo-; q) 4(3H)-Pyrimidinone, 3-methyl-6-phenyl-2-[(phenylsulfonyl)methyl]- ; r) 4(3H)-Pyrimidinone, 3-methyl-6-phenyl-2-[(phenylsulfinyl)methyl]-; s) 4-Pentenoic acid, 5-(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2-pyrimidinyl)- 4-hydroxy-, (Z)-; t) 5-Hexenoic acid, 6-(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2-pyrimidinyl)- 5-hydroxy-, (Z)-; u) 4-Pentenoic acid, 5-(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2-pyrimidinyl)-
4-hydroxy-, methyl ester, (Z)-; v) Phosphonic acid, [(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2-pyrimidinyl) cyclopropylidene]bis- .tetraethyl ester; w) Cyclopropanecarbonitrile, 2-(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl)-, trans-; x) Cyclopropanecarbonitrile, 2-( l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl)-, cis; or y) Propanedioic acid, [2-(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2-pyrimidinyl)- ethyl]-, bis(l,l-dimethylethyl) ester.
10. The compound of Claim 1 which is a) 4(3H)-Pyrimidinone, 2,3-dimethyl-6-phenyl-5-(phenylmethoxy)-; b) Phosphonic acid, [3-[l,6-dihydro-l-methyl-6-oxo-4-phenyl-5-(phenylmethoxy)-2- pyrimidinyl]propylidene]bis-, tetraethyl ester; c) Phosphonic acid, [3-(l,6-dihydro-5-hydroxy-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl)propylidene]bis-, tetraethyl ester; d) 3-(l,6-Dihydro-4-chloro-l-methyl-6-oxo-2-pyrimidinyl)-propylidene bisphosphonic acid, tetraethyl ester; e) 3-( 1,6-Dihydro- l-methyl-6-oxo-4-phenylthio-2-pyrimidinyl)-propylidene bisphosphonic acid, tetraethyl ester; or f) 3-(l,6-Dihydro-l-methyl-6-oxo-4-piperidinyl-2-pyrimidinyl)-propylidene bisphosphonic acid, tetraethyl ester.
11. A compound of Formula I for use in treating inflammation.
12. The use of Claim 11 wherein said compound is administered to a patient in need thereof in an anti-inflammatory effective amount of from 0.001 mg to 1.0 gram and is administered orally, intramuscularly, intravenously, transdermally, intra-articularly, subcutaneously, or intraperitoneally.
PCT/US1994/010571 1993-10-20 1994-09-21 Pyrimidinones as antiarthritic and anti-inflammatories WO1995011235A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP7511063A JPH09504010A (en) 1993-10-20 1994-09-21 Pyrimidinone as an anti-arthritic and anti-inflammatory agent
AU77989/94A AU7798994A (en) 1993-10-20 1994-09-21 Pyrimidinones as antiarthritic and anti-inflammatories
EP94928624A EP0724573A1 (en) 1993-10-20 1994-09-21 Pyrimidinones as antiarthritic and anti-inflammatories

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13907893A 1993-10-20 1993-10-20
US08/139,078 1993-10-20
US16167693A 1993-12-03 1993-12-03
US08/161,676 1993-12-03

Publications (1)

Publication Number Publication Date
WO1995011235A1 true WO1995011235A1 (en) 1995-04-27

Family

ID=26836841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/010571 WO1995011235A1 (en) 1993-10-20 1994-09-21 Pyrimidinones as antiarthritic and anti-inflammatories

Country Status (4)

Country Link
EP (1) EP0724573A1 (en)
JP (1) JPH09504010A (en)
AU (1) AU7798994A (en)
WO (1) WO1995011235A1 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025596A2 (en) * 1996-12-12 1998-06-18 Pharmacia & Upjohn Company Use of a 6-aryl pyrimidine compound for treating multiple sclerosis
WO2004087677A2 (en) * 2003-04-03 2004-10-14 Pharmacia Corporation Pyrimidin-4-one derivatives and their use as p38 kinase modulators
EP1503993A2 (en) * 2002-05-09 2005-02-09 Cytokinetics, Inc. Compounds, methods and compositions
EP1509507A2 (en) * 2002-05-23 2005-03-02 Merck & Co., Inc. Mitotic kinesin inhibitors
US7229993B2 (en) 2002-03-13 2007-06-12 Euro-Celtique S.A. Aryl substituted pyrimidines and the use thereof
US7625912B2 (en) 2003-12-19 2009-12-01 Merck & Co. Inc Mitotic kinesin inhibitors
US7795271B2 (en) 2003-04-03 2010-09-14 Pharmacia Corporation Substituted pyrimidinones
US8324230B2 (en) 2004-10-13 2012-12-04 Pfizer Inc. Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-Yl]-N-(2-hydroxyethyl)-4-methylbenzamide
US20140248378A1 (en) * 2011-07-07 2014-09-04 Takeda Pharmaceutical Company Limited Pyrimidinone compounds and their use
WO2015036563A1 (en) 2013-09-16 2015-03-19 Bayer Pharma Aktiengesellschaft Disubstituted trifluormethyl pyrimidinones and use thereof as ccr2 antagonists
WO2016113205A1 (en) 2015-01-13 2016-07-21 Bayer Pharma Aktiengesellschaft Substituted pentafluoroethyl pyrimidinones and use thereof
US9434695B2 (en) 2012-07-18 2016-09-06 Sunshine Lake Pharma Co., Ltd Nitrogenous heterocyclic derivatives and their application in drugs
US9750748B2 (en) 2012-12-17 2017-09-05 Takeda Pharmaceutical Company Limited Pyridazinones as DAAO enzyme inhibitors
US9902712B2 (en) 2013-12-19 2018-02-27 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
US9931340B2 (en) 2011-08-22 2018-04-03 Takeda Pharmaceutical Company Limited Pyridazinone compounds and their use as DAAO inhibitors
US10202399B2 (en) 2011-11-15 2019-02-12 Takeda Pharmaceutical Company Limited Dihydroxy aromatic heterocyclic compound
WO2021130492A1 (en) * 2019-12-23 2021-07-01 Sitryx Therapeutics Limited Carboxy derivatives with antiinflammatory properties

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001198A1 (en) * 1991-07-03 1993-01-21 The Upjohn Company Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories
EP0579425A1 (en) * 1992-07-17 1994-01-19 Rohm And Haas Company 6-arylpyrimidines and herbicidal use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001198A1 (en) * 1991-07-03 1993-01-21 The Upjohn Company Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories
EP0579425A1 (en) * 1992-07-17 1994-01-19 Rohm And Haas Company 6-arylpyrimidines and herbicidal use thereof

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025596A3 (en) * 1996-12-12 1998-08-13 Upjohn Co Use of a 6-aryl pyrimidine compound for treating multiple sclerosis
WO1998025596A2 (en) * 1996-12-12 1998-06-18 Pharmacia & Upjohn Company Use of a 6-aryl pyrimidine compound for treating multiple sclerosis
US7229993B2 (en) 2002-03-13 2007-06-12 Euro-Celtique S.A. Aryl substituted pyrimidines and the use thereof
EP1503993A2 (en) * 2002-05-09 2005-02-09 Cytokinetics, Inc. Compounds, methods and compositions
EP1503993A4 (en) * 2002-05-09 2006-05-03 Cytokinetics Inc Compounds, methods and compositions
EP1509507A4 (en) * 2002-05-23 2006-09-13 Merck & Co Inc Mitotic kinesin inhibitors
EP1509507A2 (en) * 2002-05-23 2005-03-02 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2004087677A3 (en) * 2003-04-03 2004-12-16 Pharmacia Corp Pyrimidin-4-one derivatives and their use as p38 kinase modulators
US7795271B2 (en) 2003-04-03 2010-09-14 Pharmacia Corporation Substituted pyrimidinones
AU2004226165B2 (en) * 2003-04-03 2007-11-08 Pharmacia Corporation Pyrimidin-4-one derivatives and their use as p38 kinase modulators
EA009743B1 (en) * 2003-04-03 2008-04-28 Фармация Корпорейшн Pyrimidin-4-one derivatives and their use as p38kinase modulators
AU2004226165C1 (en) * 2003-04-03 2008-07-03 Pharmacia Corporation Pyrimidin-4-one derivatives and their use as p38 kinase modulators
WO2004087677A2 (en) * 2003-04-03 2004-10-14 Pharmacia Corporation Pyrimidin-4-one derivatives and their use as p38 kinase modulators
US7625912B2 (en) 2003-12-19 2009-12-01 Merck & Co. Inc Mitotic kinesin inhibitors
US8324230B2 (en) 2004-10-13 2012-12-04 Pfizer Inc. Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-Yl]-N-(2-hydroxyethyl)-4-methylbenzamide
US20140248378A1 (en) * 2011-07-07 2014-09-04 Takeda Pharmaceutical Company Limited Pyrimidinone compounds and their use
US10085986B2 (en) * 2011-07-07 2018-10-02 Takeda Pharmaceutical Company Limited Pyrimidinone compounds and their use
US10463663B2 (en) 2011-08-22 2019-11-05 Takeda Pharmaceutical Company Limited Pyridazinone compounds and their use as DAAO inhibitors
US11129828B2 (en) 2011-08-22 2021-09-28 Takeda Pharmaceutical Company Limited Pyridazinone compounds and their use as DAAO inhibitors
US9931340B2 (en) 2011-08-22 2018-04-03 Takeda Pharmaceutical Company Limited Pyridazinone compounds and their use as DAAO inhibitors
US10202399B2 (en) 2011-11-15 2019-02-12 Takeda Pharmaceutical Company Limited Dihydroxy aromatic heterocyclic compound
US9434695B2 (en) 2012-07-18 2016-09-06 Sunshine Lake Pharma Co., Ltd Nitrogenous heterocyclic derivatives and their application in drugs
US9750748B2 (en) 2012-12-17 2017-09-05 Takeda Pharmaceutical Company Limited Pyridazinones as DAAO enzyme inhibitors
WO2015036563A1 (en) 2013-09-16 2015-03-19 Bayer Pharma Aktiengesellschaft Disubstituted trifluormethyl pyrimidinones and use thereof as ccr2 antagonists
US9902712B2 (en) 2013-12-19 2018-02-27 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
WO2016113205A1 (en) 2015-01-13 2016-07-21 Bayer Pharma Aktiengesellschaft Substituted pentafluoroethyl pyrimidinones and use thereof
WO2021130492A1 (en) * 2019-12-23 2021-07-01 Sitryx Therapeutics Limited Carboxy derivatives with antiinflammatory properties

Also Published As

Publication number Publication date
EP0724573A1 (en) 1996-08-07
JPH09504010A (en) 1997-04-22
AU7798994A (en) 1995-05-08

Similar Documents

Publication Publication Date Title
EP0724573A1 (en) Pyrimidinones as antiarthritic and anti-inflammatories
JP3526575B2 (en) Phosphonic acid derivatives
US5635495A (en) Pyrimidine bisphosphonate esters and (alkoxymethylphosphinyl)alkyl phosphonic acids as anti-inflammatories
US5397774A (en) Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories
US5273990A (en) Phosphono substituted tetrazole derivatives
US5550119A (en) Phosphono substituted tetrazole derivatives as ECE inhibitors
US6706698B2 (en) α-Substituted β-aminoethyl phosphonate derivatives
AU605340B2 (en) A process for the manufacture of novel unsaturated amino acid compounds
EP0660840B1 (en) Phosphono substituted tetrazole derivatives
EP0654035B1 (en) Phosphonoacetic esters and acids as anti-inflammatories
US5175344A (en) Unsaturated amino acids
US20030114421A1 (en) Alpha-substituted beta-aminoethyl phosphonate derivatives
US20020111488A1 (en) Beta-substitued beta-aminoethyl phosphonate derivatives
US20050124581A1 (en) Alpha-substituted heteroarylalkyl phosphonate derivatives
US20050124586A1 (en) Alpha-substituted arylalkyl phosphonate derivatives
SI8811501A (en) Process for the preparation of new unsaturated amino acide compounds
WO2004026242A2 (en) Substituted ketophosphonate inhibitors of tumor cell proliferation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994928624

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1996 624561

Date of ref document: 19960409

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1994928624

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1994928624

Country of ref document: EP